Paul Hastings LLP advised Xencor, Inc. on the offering. Xencor, Inc. (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here